CSF3 and acute myeloid leukemia: Low-dose DEC (5 mg/m2 days 1–5, 28-day cycle) plus recombinant human G-CSF was shown to reduce the incidence of AML relapse post-transplant in a randomized phase II trial of 204 patients with AML [85].